MX2019010725A - Metodos y composiciones para tratar canceres usando antisentido. - Google Patents
Metodos y composiciones para tratar canceres usando antisentido.Info
- Publication number
- MX2019010725A MX2019010725A MX2019010725A MX2019010725A MX2019010725A MX 2019010725 A MX2019010725 A MX 2019010725A MX 2019010725 A MX2019010725 A MX 2019010725A MX 2019010725 A MX2019010725 A MX 2019010725A MX 2019010725 A MX2019010725 A MX 2019010725A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- treating cancers
- irradiated
- antisense
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 4
- 150000007513 acids Chemical class 0.000 abstract 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 abstract 2
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000001015 abdomen Anatomy 0.000 abstract 1
- 229940030156 cell vaccine Drugs 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
Abstract
La presente invención se refiere a composiciones y métodos para tratar cánceres usando ácidos nucleicos antisentido (AS) dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina (IGF-1R). El AS puede administrarse a los pacientes por vía sistémica, o puede usarse para producir una vacuna autóloga de células cancerosas. En modalidades, los AS se proporcionan en una cámara de biodifusión irradiada implantable que comprende células tumorales y una cantidad eficaz de AS. Las cámaras se irradian e implantan en el abdomen de los sujetos y estimulan una respuesta inmune que ataca los tumores de manera distal. Las composiciones y métodos descritos en este documento pueden usarse para tratar muchos tipos diferentes de cáncer, por ejemplo, glioblastoma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469003P | 2017-03-09 | 2017-03-09 | |
| US201862629972P | 2018-02-13 | 2018-02-13 | |
| PCT/US2018/021706 WO2018165528A1 (en) | 2017-03-09 | 2018-03-09 | Methods and compositions for treating cancers using antisense |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010725A true MX2019010725A (es) | 2020-02-10 |
Family
ID=62838976
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010725A MX2019010725A (es) | 2017-03-09 | 2018-03-09 | Metodos y composiciones para tratar canceres usando antisentido. |
| MX2024008496A MX2024008496A (es) | 2017-03-09 | 2019-09-06 | Uso de un antisentido para la preparacion de un medicamento para tratar canceres. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008496A MX2024008496A (es) | 2017-03-09 | 2019-09-06 | Uso de un antisentido para la preparacion de un medicamento para tratar canceres. |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US10357509B2 (es) |
| EP (2) | EP3592841B1 (es) |
| JP (3) | JP7681285B2 (es) |
| KR (2) | KR20190140440A (es) |
| CN (2) | CN118750590A (es) |
| AU (2) | AU2018230458B2 (es) |
| BR (1) | BR112019018555A2 (es) |
| CA (1) | CA3054662A1 (es) |
| IL (2) | IL268872B2 (es) |
| MX (2) | MX2019010725A (es) |
| NZ (1) | NZ756820A (es) |
| RU (1) | RU2766457C2 (es) |
| SG (2) | SG10202109912XA (es) |
| WO (1) | WO2018165528A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10206942B2 (en) | 2015-04-10 | 2019-02-19 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
| EA038277B1 (ru) | 2015-10-14 | 2021-08-04 | Байо-Пат Холдингз, Инк. | P-этокси нуклеиновые кислоты для липосомальной лекарственной формы |
| MX2019003070A (es) | 2016-09-16 | 2019-10-14 | Bio Path Holdings Inc | Terapia de combinacion con oligonucleotidos antisentido liposomales. |
| CA3054662A1 (en) | 2017-03-09 | 2018-09-13 | Thomas Jefferson University | Methods and compositions for treating cancers using antisense |
| SG11201909336VA (en) | 2017-04-19 | 2019-11-28 | Bio Path Holdings Inc | P-ethoxy nucleic acids for stat3 inhibition |
| US12234457B2 (en) | 2017-04-19 | 2025-02-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for BCL2 inhibition |
| KR20250067183A (ko) * | 2018-01-24 | 2025-05-14 | 토마스 제퍼슨 유니버시티 | 생물확산 챔버 |
| CA3113812A1 (en) * | 2018-09-26 | 2020-04-02 | Thomas Jefferson University | Neoantigen compositions; and methods of preparation and use thereof |
| CA3118427A1 (en) * | 2018-11-02 | 2020-05-07 | Thomas Jefferson University | Methods and compositions for treating breast cancer using antisense |
| JP2022512896A (ja) * | 2018-11-02 | 2022-02-07 | トーマス・ジェファーソン・ユニバーシティ | アンチセンスを使用した肝細胞癌治療用の方法および組成物 |
| US20220195440A1 (en) * | 2019-03-28 | 2022-06-23 | Thomas Jefferson University | Methods for treating cancers using antisense |
| WO2024077130A1 (en) * | 2022-10-05 | 2024-04-11 | Thomas Jefferson University | Methods and compositions for treating bladder cancer |
| WO2025153084A1 (zh) * | 2024-01-19 | 2025-07-24 | 维亚臻生物技术（苏州）有限公司 | 用于抑制胰岛素样生长因子1受体表达的rna抑制剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
| CA2158347A1 (en) | 1993-03-26 | 1994-10-13 | Renato Baserga | Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides |
| US5714170A (en) | 1994-11-16 | 1998-02-03 | Thomas Jefferson University | Method of inducing resistance to tumor growth |
| US6541036B1 (en) | 1997-05-29 | 2003-04-01 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR) |
| JP2002522506A (ja) * | 1998-08-13 | 2002-07-23 | トーマス・ジェファーソン・ユニバーシティ | インスリン様増殖因子−ｉ受容体に向けられるオリゴヌクレオチドを用いた腫瘍の処置 |
| US6144553A (en) | 1998-09-09 | 2000-11-07 | Sun Microsystems, Inc. | Refrigeration cooled disk storage assembly |
| US7037335B2 (en) | 2002-11-19 | 2006-05-02 | Eagle Vision, Inc. | Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma |
| EP1597366B1 (en) | 2003-02-11 | 2012-11-21 | Antisense Therapeutics Ltd | Modulation of insulin like growth factor i receptor expression |
| US7846906B2 (en) | 2003-02-28 | 2010-12-07 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| CA2447400A1 (en) * | 2003-09-12 | 2005-03-12 | The Hospital For Sick Children | Brain tumor stem cells |
| US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
| DK2633052T3 (en) * | 2010-10-27 | 2018-07-16 | Curna Inc | TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1 |
| MX384445B (es) | 2013-09-24 | 2025-03-14 | Giner Inc | Sistema para tratamiento con gas de un implante de células. |
| US9872674B2 (en) | 2014-05-07 | 2018-01-23 | Boehringer Laboratories Inc. | Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure |
| US10206942B2 (en) | 2015-04-10 | 2019-02-19 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes |
| JP7080642B2 (ja) * | 2015-04-23 | 2022-06-06 | アプライド メディカル リソーシーズ コーポレイション | 組織取り出しシステムおよび方法 |
| EA038277B1 (ru) | 2015-10-14 | 2021-08-04 | Байо-Пат Холдингз, Инк. | P-этокси нуклеиновые кислоты для липосомальной лекарственной формы |
| CA3054662A1 (en) | 2017-03-09 | 2018-09-13 | Thomas Jefferson University | Methods and compositions for treating cancers using antisense |
| KR20250067183A (ko) * | 2018-01-24 | 2025-05-14 | 토마스 제퍼슨 유니버시티 | 생물확산 챔버 |
-
2018
- 2018-03-09 CA CA3054662A patent/CA3054662A1/en active Pending
- 2018-03-09 CN CN202410470660.XA patent/CN118750590A/zh active Pending
- 2018-03-09 IL IL268872A patent/IL268872B2/en unknown
- 2018-03-09 US US15/917,050 patent/US10357509B2/en active Active
- 2018-03-09 IL IL316679A patent/IL316679A/en unknown
- 2018-03-09 NZ NZ756820A patent/NZ756820A/en unknown
- 2018-03-09 WO PCT/US2018/021706 patent/WO2018165528A1/en not_active Ceased
- 2018-03-09 CN CN201880018150.1A patent/CN110832068A/zh active Pending
- 2018-03-09 EP EP18764973.6A patent/EP3592841B1/en active Active
- 2018-03-09 KR KR1020197029676A patent/KR20190140440A/ko active Pending
- 2018-03-09 MX MX2019010725A patent/MX2019010725A/es unknown
- 2018-03-09 JP JP2019548594A patent/JP7681285B2/ja active Active
- 2018-03-09 AU AU2018230458A patent/AU2018230458B2/en active Active
- 2018-03-09 BR BR112019018555A patent/BR112019018555A2/pt unknown
- 2018-03-09 RU RU2019130010A patent/RU2766457C2/ru active
- 2018-03-09 EP EP24157422.7A patent/EP4378531A3/en active Pending
- 2018-03-09 KR KR1020247023860A patent/KR20240116561A/ko active Pending
- 2018-03-09 US US15/916,953 patent/US20180256625A1/en not_active Abandoned
- 2018-03-09 SG SG10202109912X patent/SG10202109912XA/en unknown
- 2018-03-09 SG SG11201908054XA patent/SG11201908054XA/en unknown
-
2019
- 2019-07-22 US US16/518,253 patent/US10772904B2/en active Active
- 2019-09-06 MX MX2024008496A patent/MX2024008496A/es unknown
-
2020
- 2020-09-15 US US17/020,879 patent/US11801259B2/en active Active
-
2023
- 2023-03-01 JP JP2023030687A patent/JP7656350B2/ja active Active
- 2023-09-21 US US18/471,355 patent/US20240100078A1/en active Pending
-
2024
- 2024-10-22 AU AU2024227517A patent/AU2024227517A1/en active Pending
-
2025
- 2025-03-14 JP JP2025040952A patent/JP2025085731A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010725A (es) | Metodos y composiciones para tratar canceres usando antisentido. | |
| MX2021011760A (es) | Metodos para el tratamiento de canceres usando antisentido. | |
| CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| CY1121838T1 (el) | Συνθεσεις που περιλαμβανουν νανοσωματιδια οξειδιου του αφνιου (iv) ή οξειδιου του ρηνιου (iv) σε συνδυασμο με ιονιζουσες ακτινοβολιες για αντιμετωπιση καρκινου | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| WO2017053889A3 (en) | Flt3 directed car cells for immunotherapy | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX394252B (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf | |
| MX2017012982A (es) | Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. | |
| MX2016016115A (es) | Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr). | |
| JP2015516496A5 (es) | ||
| MX2020009773A (es) | Terapia de combinacion. | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| CO2020013968A2 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer | |
| EA201100626A1 (ru) | Лечение рака с помощью ионизирующего облучения и иммуноцитокинов | |
| EP2598139A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVING THE EFFICACY OF SYSTEMIC, HIPEC AND IP TREATMENTS AGAINST CANCER | |
| MX2018000052A (es) | Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas. | |
| MX2021005169A (es) | Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido. | |
| MX2021005168A (es) | Metodos y composiciones para el tratamiento de cancer de mama usando antisentido. | |
| MX2018015916A (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. | |
| MX2021001764A (es) | Terapia de combinacion. | |
| AR118282A1 (es) | Formulaciones inmunogénicas para el tratamiento del cáncer | |
| MX2019014842A (es) | Uso de una combinación de ivosidenib y radiación para tratar gliomas. |